Figure 1
From: Why is there persistent disease despite biologic therapy? Importance of early intervention
Remission rates across rheumatoid arthritis studies according to previous therapy.a [4]; b [5]; c [2]; d [6]; e [7]; f [8]. AGREE, Abatacept study to Gauge Remission and joint damage progression in methotrexate-naïve patients with Early Erosive Rheumatoid Arthritis; ASPIRE, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Early-Onset Rheumatoid Arthritis; COMET, Combination of Methotrexate and Etanercept in Active Early Rheumatoid Arthritis; DAS, disease activity score; IMAGE, A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis; PREMIER, Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis; PRIZE, Productivity and Remission in a Randomized Controlled Trial of Etanercept versus Standard of Care in Early Rheumatoid Arthritis.